42 related articles for article (PubMed ID: 29651918)
1. Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study.
Boccia R; Geller RB; Clendeninn N; Ottoboni T
Future Oncol; 2019 Jan; 15(3):297-303. PubMed ID: 30301373
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
[TBL] [Abstract][Full Text] [Related]
3. Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial.
Zhang Z; Yang Y; Lu P; Li X; Chang J; Zheng R; Zhou L; Chen S; Chen X; Ren B; Gu W; Jiang X; Peng J; Huang M; Feng G; Shen P; Zhang Q; Zhang B; Huang Y; He J; Chen Y; Cao J; Wang H; Li W; Wan H; Nan K; Liao Z; Zhang C; Lin Z; Zhong D; Xu Q; Liu H; Sun T; Deng Y; Zhang L
Ann Transl Med; 2020 Mar; 8(5):234. PubMed ID: 32309381
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.
Matsumoto K; Takahashi M; Sato K; Osaki A; Takano T; Naito Y; Matsuura K; Aogi K; Fujiwara K; Tamura K; Baba M; Tokunaga S; Hirano G; Imoto S; Miyazaki C; Yanagihara K; Imamura CK; Chiba Y; Saeki T
Cancer Med; 2020 May; 9(10):3319-3327. PubMed ID: 32168551
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies.
Cabanillas Stanchi KM; Ebinger M; Hartmann U; Queudeville M; Feucht J; Ost M; Koch MS; Malaval C; Mezger M; Schober S; Weber S; Michaelis S; Lange V; Lang P; Handgretinger R; Döring M
Drug Des Devel Ther; 2019; 13():3439-3451. PubMed ID: 31686784
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of aprepitant and fosaprepitant in pediatric patients.
Saito Y; Kumamoto T; Arima T; Shirakawa N; Ishimaru S; Sonoda T; Nakajima M; Sugiyama M; Arakawa A; Hashimoto H; Makino Y; Ogawa C; Yamaguchi M
Pediatr Int; 2019 Mar; 61(3):235-239. PubMed ID: 30615239
[TBL] [Abstract][Full Text] [Related]
8. Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.
Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
Future Oncol; 2018 Nov; 14(27):2849-2859. PubMed ID: 29873529
[TBL] [Abstract][Full Text] [Related]
9. Study on the method to avoid infusion-site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells.
Yamasaki M; Oda K; Ichinose T; Mizuguchi M; Tominaga S; Omoda K; Mori N; Maeda Y; Nishida T; Murakami T
Oncol Lett; 2022 Nov; 24(5):386. PubMed ID: 36238357
[TBL] [Abstract][Full Text] [Related]
10. Infusion Site Reactions: Classification in the Setting of Fosaprepitant Administration With Chemotherapy.
Segna AN; Baron RH; Cohen B
Clin J Oncol Nurs; 2020 Dec; 24(6):E79-E84. PubMed ID: 33216065
[TBL] [Abstract][Full Text] [Related]
11. Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant.
Yamasaki M; Kimura R; Mayahara S; Maeda Y; Takahashi M; Nishida T; Oda K; Murakami T
Mol Clin Oncol; 2019 Jul; 11(1):43-49. PubMed ID: 31289676
[TBL] [Abstract][Full Text] [Related]
12. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
Lundberg JD; Crawford BS; Phillips G; Berger MJ; Wesolowski R
Support Care Cancer; 2014 Jun; 22(6):1461-6. PubMed ID: 24402412
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Infusion Site Reactions in Peripheral Fosaprepitant Infusions.
Gonçalves SC; Sanches SM; Bueno CT; Villela de Castro DL; Damascena A; Santos GRC
J Infus Nurs; 2017; 40(6):380-383. PubMed ID: 29112587
[TBL] [Abstract][Full Text] [Related]
14. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.
Burns D; Kula J; Marshall S; Ashworth E; Ornelas M
Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650
[TBL] [Abstract][Full Text] [Related]
15. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
Garnock-Jones KP
Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
[TBL] [Abstract][Full Text] [Related]
16. Safety of Polysorbate 80 in the Oncology Setting.
Schwartzberg LS; Navari RM
Adv Ther; 2018 Jun; 35(6):754-767. PubMed ID: 29796927
[TBL] [Abstract][Full Text] [Related]
17. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
Chau E; Lundberg J; Phillips G; Berger M; Wesolowski R
J Oncol Pharm Pract; 2019 Jul; 25(5):1053-1057. PubMed ID: 29651918
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
